Daniel Gottlieb is an Associate Director at Broadview Ventures, a mission-driven investment organization focused on cardiovascular disease and stroke. Daniel shares responsibility for the day-to-day investment activities at Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement.

Daniel has more than 20 years of experience at medical device and biotechnology companies in corporate and business development, corporate venture capital, marketing, and strategy. Previously, Daniel was a member of the leadership team at Proteon Therapeutics, most recently as Vice President, Corporate Development. Daniel led Proteon’s business development, strategic marketing, and corporate development activities as the company progressed from a Series A startup through multiple private financings, a successful IPO, and completion of Phase 3 clinical studies. Prior to Proteon, Daniel was a strategic marketing manager in Abbott Vascular’s endovascular business unit, where he led the team developing next generation devices for peripheral artery disease. Prior to that, Daniel was at Guidant Corporation, primarily as a member of Guidant Compass, the company’s corporate venture capital, business development, and corporate strategy group. 

Daniel holds a BA from the University of Pennsylvania and an MBA from the Tuck School of Business at Dartmouth College. Daniel currently holds board roles at XII Medical (Director), Cardiosense (Director), CroíValve (Observer), Nyra Medical (Observer), and Puzzle Medical (Observer), and previously at Nido Surgical (acquired).